5-year follow-up of EV and pembrolizumab for la/mUC in the EV-103 trial

EV-103: Enfortumab vedotin plus pembrolizumab for locally advanced or metastatic urothelial carc...Подробнее

EV-103: EV + pembrolizumab as a promising first-line option for urothelial carcinomaПодробнее

Dr. Petrylak on the Results of the EV-103 Trial in Bladder CancerПодробнее

Dosing, Cycle Considerations With EV/Pembrolizumab CombinationПодробнее

First Line la/mUC Evolving Treatment Strategies: S2 Ep 4 - Round Table DiscussionПодробнее

EV/Pembro and New Treatment Options for Metastatic Bladder CancerПодробнее

EV-103: enfortumab vedotin and pembrolizumab in urothelial carcinomaПодробнее

EV-103 Study by Dr. Jonathan Rosenberg led to the FDA Approval of Enfortumab + PembrolizumabПодробнее

Counseling Patients With aUC in the Post-EV/Pembrolizumab WorldПодробнее

KEYNOTE-057: extended follow-up of pembrolizumab in bladder cancerПодробнее

ESPID 2025: Let's Meet in BucharestПодробнее

EV in cisplatin-ineligible patients with locally advanced or metastatic urothelial cancerПодробнее

Webinar Grand Round 5 (May 11, 2024)Подробнее

CAR-Ts in multiple myeloma: their current role and the futureПодробнее

Lecture 4-7a: Cases from daily practice; Patients with late challengesПодробнее

2024 EC3-PPM-Navarro Bringas, Eduardo-Leveraging Digital Twins Towards an Occupant-Centric Built ...Подробнее

The real-world efficacy of CAR-T cells in post-transplant relapsed B-ALLПодробнее

Barriers to enrollment in clinical trials for patients with B-NHL who progress after CAR-T therapyПодробнее